The niaid mission and scope including research and development of vaccines and therapeutics for the prevention and treatment of diseases of human concern, including malaria. The vaccine research…
Active Awarded Last action
- Contract number
- 75N91023F00017
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,872,547
Award facts
- Contract value 43% obligated
-
- $5,872,547.00 Current, with exercised options
- $13,618,140.00 Potential, with all options
- Completion date 44% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $560,278 | |
| Exercise an Option | $651,914 | |
| Original award | $4,660,355 |
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $13,618,140.00 contract supports the NIAID's mission of research and development of vaccines and therapeutics for diseases of human concern, including malaria. The contract does not have a set-aside designation. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute, providing comprehensive biomedical research and facilities support services to federal agencies, with a focus on the National Institutes of Health. The contract work will take place in Frederick, Maryland, and the period of performance runs through September 23, 2030.
Description
The niaid mission and scope including research and development of vaccines and therapeutics for the prevention and treatment of diseases of human concern, including malaria. The vaccine research center (VRC) has developed two monoclonal antibodies (m
Quick answers
Who was awarded contract 75N91023F00017?
75N91023F00017 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2023.
How much is contract 75N91023F00017 worth?
The government has obligated $5,872,547 on 75N91023F00017. Its potential value, with all options, is $13,618,140.
Which agency awarded contract 75N91023F00017?
National Cancer Institute (National Institutes of Health) awarded 75N91023F00017, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91023F00017 an order under another contract?
Yes. 75N91023F00017 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00017 competed?
The extent of competition for 75N91023F00017 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award